Flindr Therapeutics is at the forefront of precision oncology, developing first-in-class small molecule inhibitors aimed at transforming cancer treatment. Central to their approach is the ImmunoGram Drug Discovery Engine, which facilitates the identification of novel drug targets within both cancer and immune cells. This innovative platform has led to the discovery of RNF31, a key target involved in the regulation of the NF-kB signaling pathway, which is frequently hyperactivated in various cancers. By inhibiting RNF31, Flindr aims to block this aberrant signaling, thereby inducing cell death in tumor cells and offering a promising therapeutic strategy for patients with specific cancer types.

In addition to the RNF31 program, Flindr is advancing a second program that also utilizes the ImmunoGram Drug Discovery Engine to target another novel drug target, with potential applications across multiple solid tumors. The company has developed a robust data package supporting these initiatives, which includes reliable biomarkers to identify patients who are likely to benefit from RNF31 inhibitors. Flindr's commitment to leveraging cutting-edge science and technology positions it as a leader in the development of precision oncology therapies, with the goal of delivering transformative treatments to cancer patients.

Netherlands

Flindr Therapeutics B.V. is a precision oncology therapeutics company that is developing first-in-class small molecule inhibitors. The company has secured €20 million in Series A financing to advance its pipeline of precision oncology treatments.

Flindr Therapeutics

Company Details